Trial Profile
A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs DCVAC LuCa (Primary) ; Hydroxychloroquine (Primary) ; Interferon alpha (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Non-small cell lung cancer
- Focus First in man; Therapeutic Use
- Sponsors SOTIO
- 03 May 2022 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Final analysis results evaluating the effect of addition of Dendritic-cell vaccine to the standard of care chemotherapy in patients with stage IV NSCLC are presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2019 According to a SOTIO media release, Libor Havel is the principal investigator of this trial.